F-box and leucine rich repeat protein 3Genealiases: FBL3 · FBL3A · FBXL3A · IDDSFAS
Q-omics provides the consensus-scored FBXL3 profile across patient tissues and cancer cell-line models. FBXL3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FBXL3 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, FBXL3 RNA expression shows 20,286 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where FBXL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXL3 survival associations across molecular data types. FBXL3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXL3 RNA expression–survival associations across cancer types. High FBXL3 expression shows unfavorable associations in ESCA, but favorable associations in KIRC, COAD, HNSC, THYM and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FBXL3 RNA expression.
This table summarizes FBXL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FBXL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXL3 shows lower tumor expression in THCA, KICH, LUAD, KIRP, LUSC and UCEC. The THCA box plot shows higher FBXL3 RNA expression in normal versus tumor tissue (log2 FC = −1.380, t-test p < 0.001).
This table shows molecular features associated with FBXL3 in patient tissues and cancer cell lines. In patient samples, FBXL3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
